Alexion Pharmaceuticals Inc

ALXN 
(NASDAQ) 
 
$ 127.70
Updated 09:00:07
Change % 0.00% Stock price unchanged
Change 0.00 Stock price unchanged
Volume 991,883
High $ 128.13
Low $ 122.35
Open $ 122.63
ISIN
Prev close $ 121.49
# of shares 222.86M
Market cap 28,459M USD
Intraday

Market closed
Alexion Pharmaceuticals Inc
Market is closed, opens at 14:30
 
Price development Latest 1 week 1 month 3 months 6 months 1 year
 
  127.70 3.0% Stock price increasing 8.4% Stock price increasing -6.4% Stock price decreasing 12.7% Stock price increasing -10.8% Stock price decreasing
Powered by TradingView

News about Alexion Pharmaceuticals Inc

  • English
  • Regulatory news

Company profile

Alexion Pharmaceuticals specializes in developing and marketing drugs for life-threatening medical conditions. Its blockbuster product is Soliris, which is the only approved therapy for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, two ultra-rare blood disorders, and was recently approved in general myasthenia gravis. Strensiq and Kanuma target other ultra-rare metabolic diseases. Alexion's pipeline targets areas of high unmet need and complement-mediated disorders.

Copyright Berlingske Media 2018  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
17 October 2018 11:12:46
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20181005.3 - EUROWEB2 - 2018-10-17 12:12:46 - 2018-10-17 11:12:46 - 1000 - Website: OKAY